Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicenter, Phase 1b/2 Study to Establish Safety, Tolerability, and Optimal Dosing Strategy of GLR2007 in Subjects With Advanced Solid Tumors

NCT04444427 is registered in ClinicalTrials.gov with Gan and Lee Pharmaceuticals, USA as lead sponsor.

NCT NCT04444427
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04444427 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicenter, Phase 1b/2 Study to Establish Safety, Tolerability, and Optimal Dosing Strategy of GLR2007 in Subjects With Advanced Solid Tumors
Lead sponsor
Gan and Lee Pharmaceuticals, USA
Phase
Phase 1/2
Overall status
Completed
Start date
July 15, 2020
Completion date
July 29, 2022
Enrollment
19 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma multiforme, non-small cell lung cancer